subject: Astellas Pharma Inc.: Pharmavitae Profile - Market Research Report On Aarkstore Enterprise [print this page] Introduction Introduction
This analysis examines the historical and forecast performance for Astellas in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
Gain insight into Astellass strategic outlook across the next 6 years
Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Astellas over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the companys prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
Benchmark Astellass performance against key rivals in the prescription pharmaceutical sector
Determine whether Astellass pipeline will be able to offset the sharp decline facing its marketed portfolio
Table of Contents :
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 200315 6
Financial performance, 200315 7
Astellas: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 13
Chapter 3 Quarterly news update 20
Latest prescription pharma product news 20
Latest corporate news 21
Future product milestones 24
Chapter 4 Company introduction 25
Key findings 25
Background 26
Key corporate developments 26
M&A history 28
Chapter 5 Company sales 30
Key findings 30
Prescription pharmaceutical sales and growth rate analysis, 200315 31
Product analysis 32
Therapy area analysis 42
Geographic analysis 44
Launch/core/expiry analysis 46
Molecule type analysis 52
Externalization analysis 54
Chapter 6 Company financials 56
Key findings 56
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 200309 57
Operating costs and profit analysis 58
Operating cost ratio and profit margin analysis, 200915 61
